Tumor Necrosis Factor-alpha is a Potent Endogenous Mutagen That Promotes Cellular Transformation
Overview
Authors
Affiliations
Tumor necrosis factor-alpha (TNF-alpha) is an important inflammation cytokine without known direct effect on DNA. In this study, we found that TNF-alpha can cause DNA damages through reactive oxygen species. The mutagenic effect of TNF-alpha is comparable with that of ionizing radiation. TNF-alpha treatment in cultured cells resulted in increased gene mutations, gene amplification, micronuclei formation, and chromosomal instability. Antioxidants significantly reduced TNF-alpha-induced genetic damage. TNF-alpha also induced oxidative stress and nucleotide damages in mouse tissues in vivo. Moreover, TNF-alpha treatment alone led to increased malignant transformation of mouse embryo fibroblasts, which could be partially suppressed by antioxidants. As TNF-alpha is involved in chronic inflammatory diseases, such as chronic hepatitis, ulcerative colitis, and chronic skin ulcers, and these diseases predispose the patients to cancer development, our results suggest a novel pathway through which TNF-alpha promotes cancer development through induction of gene mutations, in addition to the previously reported mechanisms, in which nuclear factor-kappaB activation was implicated.
Obesity increases DNA damage in the breast epithelium.
Gaber M, Quentel A, Holmes J, Lepetit C, Triki H, Wilson A Breast Cancer Res. 2025; 27(1):11.
PMID: 39838489 PMC: 11753040. DOI: 10.1186/s13058-025-01961-7.
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.
Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.
PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.
Profir M, Rosu O, Cretoiu S, Gaspar B Microorganisms. 2024; 12(5).
PMID: 38792785 PMC: 11124004. DOI: 10.3390/microorganisms12050955.
Huang Y, Zhang Q, Guo Z, Deng G, Chen R, Zheng Y Cancer Med. 2023; 12(13):14718-14730.
PMID: 37199052 PMC: 10358244. DOI: 10.1002/cam4.6095.
Eder L, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J Curr Oncol. 2023; 30(1):1146-1150.
PMID: 36661736 PMC: 9858310. DOI: 10.3390/curroncol30010087.